Article Details

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years ...

Retrieved on: 2022-01-31 06:29:07

Tags for this article:

Click the tags to see associated articles and topics

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years .... View article details on hiswai:

Excerpt

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up